Anglo-Swiss commodity trading and mining giant
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
Beard and Gibson face charges of conspiring to make corrupt payments to government and state-owned oil officials in Nigeria, Cameroon and the Ivory Coast. The six former Glencore traders deny the allegations as their trial approaches. The case follows a 2024 verdict against Javier Aguilar for corruption at a major trading house.